1Longo DL.DR‘s orders:human antibody kills tumors by direct signaling[].Nature Medicine.2002
2Davis TA,Grilo Lopez AJ,Wite CA,et al.Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin’s lymphoma: safety and efficacy of retreatment[].Journal of Clinical Oncology.2000
3Coiffier B,Lepage E,Briere J,et al.CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma[].New England Journal of Homeopathy.2002
4McLaughlin P,Grillo-Lopez AJ,Link BK,et al.Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program[].Journal of Clinical Oncology.1998
5Davis TA,Grilo Lopez AJ,Wite CA,et al.Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin’s lymphoma: safety and efficacy of retreatment[].Journal of Clinical Oncology.2000
6Golay J,Zaffaroni L,Vaccari T,et al.Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis[].Blood.2000
7Smith MR.Rituximab (monoclonal anti-CD20 antibody) : Mechanisms of action and resistance[].Oncegene.2003
8Selenko,N,Maidic,O,Draxier,S.CD20 antibody (C2B8)-induced apoptosis of lymphoma cells promotes phagocytosis by dendritic cells and cross-priming of CD8+ cytotoxic T cells[].Leukemia.2001
9MARCUS R,IMRIE K. BELCH A,et al.CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma[].Blood.2005
10Pfreundschuh,M,Trumper,L,Osterborg,A,Pettengell,R,Trneny,M,Imrie,K,Ma,D,Gill,D,Walewski,J,Zinzani,PL,Stahel,R,Kvaloy,S,Shpilberg,O,Jaeger,U,Hansen,M,Lehtinen,T,Lopez-Guillermo,A,Corrado,C,Scheliga,A,Milpied,N,Mendila,M,Rashford,M,Kuhnt,E,Loeffler,M.CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group[].The Lancet Oncology.2006
